Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr

NCT03469960 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

265

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer Metastatic

Interventions

DRUG: Ipilimumab
DRUG: Nivolumab

Sponsor

Intergroupe Francophone de Cancerologie Thoracique